Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

Pfizer’s battle over the safety label for its birth control injection has finally come to a close. The pharma giant announced that the Food and Drug Administration approved its new safety warning ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Pfizer Inc (PFE) announced an update on their ongoing clinical study. modRNA shingles pursuit from Pfizer and BioNTech now centers on the terminated Phase 1/2 study formally titled “A PHASE 1/2 ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...